These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 27817944)

  • 1. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
    Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
    Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial.
    Masuda N; Takahashi M; Nakagami K; Okumura Y; Nakayama T; Sato N; Kanatani K; Tajima K; Kashiwaba M
    Jpn J Clin Oncol; 2017 May; 47(5):385-392. PubMed ID: 28158579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
    Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
    Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
    Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
    J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
    Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
    Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
    Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
    Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
    Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
    Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
    Gradishar WJ; Kaklamani V; Sahoo TP; Lokanatha D; Raina V; Bondarde S; Jain M; Ro SK; Lokker NA; Schwartzberg L
    Eur J Cancer; 2013 Jan; 49(2):312-22. PubMed ID: 22954665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
    Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
    Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
    Diéras V; Wildiers H; Jassem J; Dirix LY; Guastalla JP; Bono P; Hurvitz SA; Gonçalves A; Romieu G; Limentani SA; Jerusalem G; Lakshmaiah KC; Roché H; Sánchez-Rovira P; Pienkowski T; Seguí Palmer MÁ; Li A; Sun YN; Pickett CA; Slamon DJ
    Breast; 2015 Jun; 24(3):182-90. PubMed ID: 25747197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
    Rochlitz C; Bigler M; von Moos R; Bernhard J; Matter-Walstra K; Wicki A; Zaman K; Anchisi S; Küng M; Na KJ; Bärtschi D; Borner M; Rordorf T; Rauch D; Müller A; Ruhstaller T; Vetter M; Trojan A; Hasler-Strub U; Cathomas R; Winterhalder R;
    BMC Cancer; 2016 Oct; 16(1):780. PubMed ID: 27724870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.